Activity-Based vs. Purity-Based QC Metrics for Protein Synthesis Reagents

A certificate of analysis says a lot passed. The experiment that depends on it fails anyway. That gap is the starting point for understanding what is wrong with how protein synthesis reagents get certified for use: the dominant QC paradigm rests on a basic category error, using structural readouts to certify functional fitness. A280, BCA, and Bradford assays all measure total protein mass, and they do so without discrimination, folded protein, misfolded protein, denatured protein, and contaminant protein all contribute to the same single number. That number cannot tell anyone which fraction of it is actually capable of doing the job the protein was made for.

SDS-PAGE suffers from the same blindness in a different form. A band at the expected molecular weight confirms that a protein of roughly the right size is present in the lane. It says nothing about whether that protein folded correctly, whether it retains the conformation needed to catalyze a reaction or bind a target, or whether a meaningful fraction of it is aggregated junk sitting at the same apparent weight. A reagent lot can clear every purity specification on its certificate of analysis and still produce no usable signal downstream. It is the predictable consequence of grading a reagent on a property, mass, that has no fixed relationship to the property that actually matters, function.

How purity metrics became the default

Purity metrics did not win out because anyone believed mass was a good proxy for function. They won because they were cheap, fast, and available decades before the applications that would expose their limits existed at any scale. SDS-PAGE, A280, and colorimetric assays need no target-specific reagents and produce comparable results across virtually any protein, which made them the obvious default in an era when reagent QC was built around simple recombinant proteins with straightforward behavior. Once a lab or a supplier had a gel rig and a spectrophotometer, testing any new protein lot cost almost nothing in new infrastructure.

That convenience hardened into habit, and habit hardened into standard practice. A review from UCL, Merck, and CPI points to a lack of technology transfer and knowledge sharing as a key limiting factor in the development of cell-free protein synthesis, making the barrier institutional rather than a matter of which assay is easiest to run. Regulatory precedent reinforces the pattern: no established quality framework exists specifically for cell-free protein synthesis reagents, so manufacturers reach for the QC language regulators already know how to read. Aw's 2026 perspective in Microbiology names this directly, citing the absence of CFPS-specific quality and regulatory expectations as one of the persistent barriers standing in the way of industrial adoption. Even the field's own attempt at reform preserved the hierarchy it should have overturned: the 2021 Nature Communications minimum-QC framework from de Marco and colleagues treats functional activity assays as extended tests rather than minimum requirements, which keeps them optional in the very guidance manufacturers are supposed to follow. The flaw in purity-based QC was never a secret. What kept it in place was the absence of anything built to replace it.

How CFPS Reagents Expose This Flaw More Severely Than Conventional Reagent Systems

A conventional reagent delivers a defined protein into an assay, and purity, however imperfect a proxy, at least bears some relationship to what that protein will do. A cell-free protein synthesis reagent is a different animal. The extract itself is the enzyme system, so measuring the purity of its components answers a different question than whether it can actually synthesize protein, not a weaker version of the same question. A CFPS lysate has to sustain coupled transcription, translation, energy regeneration, and folding assistance all at once, and in eukaryotic systems it has to support post-translational modification on top of all of that. None of that coordinated activity appears in a measurement of total protein mass.

Wu and colleagues, writing in Biotechnology and Bioengineering in 2026, frame this as an industrial problem as much as a scientific one: demonstrating consistent quality in a whole cell extract is difficult without a full understanding of the raw material's attributes and how they interact with reaction conditions and the final product. Batch-to-batch variation in cell-free extract is among the most cited problems in the field; it originates in exactly the components a purity gel cannot resolve: buffer composition, nuclease and protease load, metabolite concentrations, and ribosome integrity. The PURE system offers an instructive case study in just how far this problem runs. Built from 36 defined, purified components specifically to eliminate crude-extract variability, PURE trades lower batch variation for lower yield and higher cost, and even then, it still needs activity verification to confirm that its defined components are functional and not merely present in the tube. If a system built entirely from individually purified parts still can't skip activity testing, purity was never going to be an adequate stand-in for function in a crude extract. Tong and colleagues, writing in Synthetic and Systems Biotechnology in 2026, identify standardization and cost among several key bottlenecks hindering industrialization of eukaryotic CFPS, both of which are downstream consequences of QC that cannot confirm batch-to-batch functional equivalence. The question that remains is what a QC method would need to measure to close that gap.

What Activity-Based QC Measures and How It Is Implemented

Activity-based QC certifies what a reagent does under conditions that resemble how it will actually be used, rather than what it contains under denaturing conditions that bear no resemblance to the reaction it's meant to run. For a CFPS lysate, the standard activity metric is protein synthesis yield from a reporter construct, run as a standardized test on every batch. Fluorescent proteins such as sfGFP and deGFP, or luciferase, serve as the typical reporters, chosen because their output exercises transcription, translation, and folding all in a single run.

That single number carries more diagnostic weight than it might first appear to. Reporter yield integrates several distinct failure modes at once: degraded ribosomes cut translation efficiency, a compromised energy-regeneration system reduces yield as the reaction runs longer, and elevated protease activity degrades the product as it's made, all invisible on a gel or in an A280 reading and all immediately visible in a yield measurement. For downstream protein characterization, the activity assay gets specific to the target: enzyme kinetics such as kcat and Km, binding affinity measured by SPR, BLI, or ELISA, or a cell-based functional readout, each one certifying the exact property the lot needs to have for its intended use. A study from Bristol-Myers Squibb, published in Analytical Chemistry in 2024, makes the underlying substitution explicit: using total protein concentration as a stand-in for in-assay performance misrepresents the actual concentration of usable material and introduces lot-to-lot uncertainty into downstream measurements, a problem that activity-normalized concentration corrects. The question that follows is whether this kind of measurement, taken on a crude, unpurified reaction, can be trusted to predict how a purified protein will eventually behave.

The evidence that activity rankings from CFPS reactions predict purified-protein performance

Independent studies point the same way: activity measured in an unpurified CFPS reaction correlates closely with the ranking that purified protein would eventually produce. Activity-based QC can therefore gate variant selection before purification ever happens. A 2026 study in FEBS Open Bio ran direct plasminogen-activation assays, in microplate format, on unpurified CFPS reactions containing staphylokinase variants. The activity rankings those crude reactions produced closely matched the rankings obtained from purified protein, demonstrating that the functional signal survives being measured inside a complex, unpurified reaction matrix.

Arcadia Science reported a parallel result in 2025, screening protease variants directly in CFPS reactions and as purified proteins at matched concentrations, and found the same trend of activity in both formats. That agreement confirms that the differences observed between variants in CFPS reflect real differences in protease activity rather than noise introduced by expression level. Both studies operationalize the same underlying principle: for the purpose of ranking variants, activity measured in CFPS is sufficient on its own, and purification becomes something done to the winners afterward rather than a prerequisite for finding out which candidates are worth pursuing in the first place. That inversion matters because it removes a multi-week purification-and-assay cycle from the front of the workflow and replaces it with a same-day, plate-based readout, which changes how many variants a lab can reasonably afford to test in a single round.

Where the gap becomes most consequential: challenging proteins

The clearest illustration of what purity metrics miss comes from colicin E3. Co-expressing its immunity protein inside the CFPS reaction increases cell-killing activity by five orders of magnitude, an effect that no purity-based readout can see and that only a functional assay can detect at all. For toxic, insoluble, and multi-domain proteins expressed through cell-free synthesis, a purity measurement answers the wrong question. An activity assay is the only tool that can confirm whether the protein is active and correctly folded.

Colicin M provides a second case. Enriching the CFPS lysate with chaperones raises its solubility from a minority of the expressed product to nearly complete solubility, a transformation that a gel band or an A280 reading cannot register once solubility has already been achieved, but that an activity assay certifies directly. Tong and colleagues describe eukaryotic CFPS systems as offering intrinsic post-translational modification machinery along with a complex molecular chaperone network, both of which support correct conformation and biological activity in complex proteins, and neither of which purity measurement has any way of confirming. Shipping a lot that passed its SDS-PAGE check is not a cautious decision for this class of targets. It simply tells you nothing. The only QC method that can be trusted here is the one that measures the biological property the downstream experiment actually depends on.

How activity-based QC enables high-throughput variant screening at scale

Scale changes what counts as adequate QC. Once a screening campaign runs into the hundreds or thousands of variants across automated plate workflows, activity-based readouts become the only approach capable of producing decision-relevant signal without turning purification into a bottleneck that slows the whole campaign down. An autonomous CFPS optimization effort reported in 2026 ran more than 36,000 reactions across 580 automated plates, using protein titer, a functional output, as the primary metric driving decisions from one round to the next, not purity.

That design choice reflects a practical constraint built into plate-based screening: each well holds a reaction rather than a purification column, so the measurement taken from it has to work on crude reaction volumes directly. Fluorescence, luminescence, enzyme activity, and ELISA-based binding assays are all naturally compatible with plate formats and parallelize easily, and they are already standard currency in high-throughput biology, so folding activity-based lot QC into an existing workflow requires no new instrumentation for labs already running screens at this scale. OpenCFPS™ reagents are built around this same logic: engineered for plate-based and automated workflows, with lot-level QC data published openly, so that an activity-verified lot becomes a traceable, comparable unit across an entire screening campaign rather than a reagent whose performance has to be re-established with every new shipment that arrives.

The Real Objection to Activity-Based QC

The strongest argument against activity-based QC is that it does not generalize. Activity assays are target-specific, and confirming that one lot produces active Factor Xa says nothing about whether that same lot will produce active VHH antibody fragments. That objection carries real weight when the question is releasing a finished protein product, where every target genuinely does require its own functional test.

It does not carry the same weight when the question is certifying the reagent that synthesizes the protein in the first place. A CFPS reagent's activity metric is synthesis yield from a standardized reporter construct, and that reporter exercises the exact same transcription, translation, and folding machinery that any target protein will eventually rely on, regardless of what that target turns out to be. A single reporter assay, run the same way on every lot, covers the full productive capacity of the reagent rather than one narrow slice of it. The UCL, Merck, and CPI review argues for a quality-by-design approach to extract production, built on the principle that raw material attributes should be understood and controlled rather than merely described after the fact, and a standardized reporter-based release test fits that principle directly. What remains unresolved is regulatory: no established framework yet tells manufacturers which activity-based tests to standardize on or how to report them. That is a solvable gap, not a structural flaw in the method itself, and closing it is a matter of building the framework the field has so far done without.